Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Spyre Therapeutics (SYRE) Gross Profit: 2015-2023

Historic Gross Profit for Spyre Therapeutics (SYRE) over the last 5 years, with Jun 2023 value amounting to $688,000.

  • Spyre Therapeutics' Gross Profit rose 10.08% to $688,000 in Q2 2023 from the same period last year, while for Jun 2023 it was $1.2 million, marking a year-over-year decrease of 93.03%. This contributed to the annual value of $886,000 for FY2023, which is 61.96% down from last year.
  • Spyre Therapeutics' Gross Profit amounted to $688,000 in Q2 2023, which was up 247.47% from $198,000 recorded in Q1 2023.
  • Spyre Therapeutics' Gross Profit's 5-year high stood at $12.0 million during Q2 2021, with a 5-year trough of $168,000 in Q4 2022.
  • For the 3-year period, Spyre Therapeutics' Gross Profit averaged around $3.4 million, with its median value being $688,000 (2023).
  • In the last 5 years, Spyre Therapeutics' Gross Profit plummeted by 98.55% in 2022 and then grew by 10.08% in 2023.
  • Quarterly analysis of 3 years shows Spyre Therapeutics' Gross Profit stood at $3.6 million in 2021, then tumbled by 95.39% to $168,000 in 2022, then climbed by 10.08% to $688,000 in 2023.
  • Its last three reported values are $688,000 in Q2 2023, $198,000 for Q1 2023, and $168,000 during Q4 2022.